TY - JOUR
T1 - Adversomics
T2 - A new paradigm for vaccine safety and design
AU - Whitaker, Jennifer A.
AU - Ovsyannikova, Inna G.
AU - Poland, Gregory A.
N1 - Funding Information:
The authors were supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers U01AI089859, N01AI40065, R37AI048793, and R01AI033144. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. GA Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. GA Poland offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Sanofi Pasteur, Dynavax, Novartis Vaccines and Therapeutics, PAXVAX Inc, Emergent Biosolutions, Adjuvance, and Vaxness. GA Poland and IG Ovsyannikova hold two patents related to vaccinia and measles peptide research. JA Whitaker receives funding for Mayo Clinic research from Pfizer Independent Grants for Learning and Change. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© Informa UK, Ltd..
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Despite the enormous population benefits of routine vaccination, vaccine adverse events (AEs) and reactions, whether real or perceived, have posed one of the greatest barriers to vaccine acceptance-and thus to infectious disease prevention-worldwide. A truly integrated clinical, translational, and basic science approach is required to understand the mechanisms behind vaccine AEs, predict them, and then apply this knowledge to new vaccine design approaches that decrease, or avoid, these events. The term 'adversomics' was first introduced in 2009 and refers to the study of vaccine adverse reactions using immunogenomics and systems biology approaches. In this review, we present the current state of adversomics research, review known associations and mechanisms of vaccine AEs/reactions, and outline a plan for the further development of this emerging research field.
AB - Despite the enormous population benefits of routine vaccination, vaccine adverse events (AEs) and reactions, whether real or perceived, have posed one of the greatest barriers to vaccine acceptance-and thus to infectious disease prevention-worldwide. A truly integrated clinical, translational, and basic science approach is required to understand the mechanisms behind vaccine AEs, predict them, and then apply this knowledge to new vaccine design approaches that decrease, or avoid, these events. The term 'adversomics' was first introduced in 2009 and refers to the study of vaccine adverse reactions using immunogenomics and systems biology approaches. In this review, we present the current state of adversomics research, review known associations and mechanisms of vaccine AEs/reactions, and outline a plan for the further development of this emerging research field.
KW - drug-related side effects and adverse reactions
KW - genetic association studies
KW - genomics
KW - immunogenetics
KW - individualized medicine
KW - polymorphism
KW - single nucleotide
KW - systems biology
KW - vaccination
KW - vaccines
KW - viral vaccines
UR - http://www.scopus.com/inward/record.url?scp=84931830141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931830141&partnerID=8YFLogxK
U2 - 10.1586/14760584.2015.1038249
DO - 10.1586/14760584.2015.1038249
M3 - Review article
C2 - 25937189
AN - SCOPUS:84931830141
SN - 1476-0584
VL - 14
SP - 935
EP - 947
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 7
ER -